• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Vitrolife (OM:VITR) Shares Climbed, What Is Driving Attention Now?

    Simply Wall St·10/25/2026 18:24:28
    Listen to the news

    Vitrolife (OM:VITR) is back in focus after its third quarter update, with SEK 884 million in sales and SEK 127 million in net income. This has prompted fresh attention on the stock’s recent momentum.

    Vitrolife’s latest report lands after a sharp short term rebound, with a 1 day share price return of 5.94% and a 90 day share price return of 27.25%. However, the 1 year total shareholder return is still down 27.25%, which signals improving momentum from a weak longer track record.

    Compare Vitrolife’s rebound with a curated set of resilient healthcare and biotech plays by scanning our 221 resilient stocks with low risk scores for ideas with sturdier risk profiles.

    Vitrolife now pairs a recovering earnings picture with a sharply reset share price. The business looks stronger than a year ago. Is the stock still on the clearance rack or already fully marked up?

    Most Popular Narrative: 16% Undervalued

    Vitrolife's most followed narrative points to a fair value of SEK130.20 per share, compared with the latest close at SEK108.80. This puts the current rebound in the context of a still meaningful implied discount.

    Recent margin compression has been heavily influenced by adverse currency movements and one-off legal/admin costs. As these headwinds abate and investments in sales, marketing, and operational excellence yield results, EBITDA margins should recover, driving improved earnings growth.

    See why 4 investors see Vitrolife as 16% undervalued.

    Result: Fair Value of SEK130.20 (UNDERVALUED)

    Still, the narrative can break if currency swings continue to pressure margins, or if IVF treatment delays in key markets linger longer than expected.

    Find out about the key risks to this Vitrolife narrative.

    Next Steps

    Momentum looks to be turning more positive around Vitrolife, so it makes sense to pressure test the story against your own expectations and risk tolerance. If you want to see what has investors optimistic, take a closer look at the 3 key rewards.

    Looking for more investment ideas beyond Vitrolife?

    If Vitrolife has your attention, do not stop here. Broaden your watchlist with other opportunities that share strong fundamentals, proven cash generation, or resilient dividends.